UBS analyst Graham Doyle downgraded Fresenius Medical Care to Neutral from Buy with a price target of EUR 42, down from EUR 43.50. The analyst views consensus earnings expectations as “too high.” The company needs to increase EBIT guidance by 5% for the year to meet to current consensus, the analyst tells investors in a research note. Meanwhile, potential overhangs on Fresenius Medical shares include Fresenius possibly selling more of its stake and Novo Nordisk’s data later this year showing renal benefit, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FMS:
- Fresenius Medical price target raised to EUR 46 from EUR 38 at Deutsche Bank
- Fresenius Medical price target raised to EUR 45 from EUR 42 at Credit Suisse
- Fresenius Medical price target raised to EUR 38 from EUR 36 at Barclays
- Fresenius Medical price target raised to EUR 54 from EUR 50.90 at Berenberg
- Fresenius Medical price target raised to EUR 38 from EUR 28.60 at JPMorgan